|
1
|
Valle JW, Kelley RK, Nervi B, Oh DY and
Zhu AX: Biliary tract cancer. Lancet. 397:428–444. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brindley PJ, Bachini M, Ilyas SI, Khan SA,
Loukas A, Sirica AE, The BT, Wongkham S and Gores GJ:
Cholangiocarcinoma. Nat Rev Dis Primers. 7:652021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48.
2023.PubMed/NCBI
|
|
4
|
Torre LA, Siegel RL, Islami F, Bray F and
Jemal A: Worldwide burden of and trends in mortality from
gallbladder and other biliary tract cancers. Clin Gastroenterol
Hepatol. 16:427–437. 2018. View Article : Google Scholar
|
|
5
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA;
WHO classification of tumours editorial board: The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020. View Article : Google Scholar :
|
|
6
|
Nakanuma Y and Kakuda Y: Pathologic
classification of cholangiocarcinoma: New concepts. Best Pract Res
Clin Gastroenterol. 29:277–293. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roa JC, García P, Kapoor VK, Maithel SK,
Javle M and Koshiol J: Gallbladder cancer. Nat Rev Dis Primers.
8:692022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vogel A, Bridgewater J, Edeline J, Kelley
RK, Klümpen HJ, Malka D, Primrose JN, Rimassa L, Stenzinger A,
Valle JW, et al: Biliary tract cancer: ESMO Clinical Practice
Guideline for diagnosis, treatment and follow-up. Ann Oncol.
34:127–140. 2023. View Article : Google Scholar
|
|
9
|
Ruff SM, Cloyd JM and Pawlik TM: Annals of
surgical oncology practice guidelines series: Management of primary
liver and biliary tract cancers. Ann Surg Oncol. 30:7935–7949.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baria K, De Toni EN, Yu B, Jiang Z, Kabadi
SM and Malvezzi M: Worldwide incidence and mortality of biliary
tract cancer. Gastro Hep Adv. 1:618–626. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lamarca A, Edeline J and Goyal L: How I
treat biliary tract cancer. ESMO Open. 7:1003782022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Benson AB, D'Angelica MI, Abrams T, Abbott
DE, Ahmed A, Anaya DA, Anders R, Are C, Bachini M, Binder D, et al:
NCCN Guidelines® insights: Biliary tract cancers,
version 2.2023. J Natl Compr Canc Netw. 21:694–704. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harding JJ, Khalil DN, Fabris L and
Abou-Alfa GK: Rational development of combination therapies for
biliary tract cancers. J Hepatol. 78:217–228. 2023. View Article : Google Scholar
|
|
14
|
Palmieri LJ, Lavolé J, Dermine S, Brezault
C, Dhooge M, Barré A, Chaussade S and Coriat R: The choice for the
optimal therapy in advanced biliary tract cancers: Chemotherapy,
targeted therapies or immunotherapy. Pharmacol Ther.
210:1075172020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lamarca A, Barriuso J, McNamara MG and
Valle JW: Molecular targeted therapies: Ready for 'prime time' in
biliary tract cancer. J Hepatol. 73:170–185. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Galluzzi L, Vitale I, Aaronson SA, Abrams
JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews
DW, et al: Molecular mechanisms of cell death: Recommendations of
the nomenclature committee on cell death 2018. Cell Death Differ.
25:486–541. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koren E and Fuchs Y: Modes of regulated
cell death in cancer. Cancer Discov. 11:245–265. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An Iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang X, Stockwell BR and Conrad M:
Ferroptosis: Mechanisms, biology and role in disease. Nat Rev Mol
Cell Biol. 22:266–282. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weinlich R, Oberst A, Beere HM and Green
DR: Necroptosis in development, inflammation and disease. Nat Rev
Mol Cell Biol. 18:127–136. 2017. View Article : Google Scholar
|
|
21
|
Wyllie AH: Glucocorticoid-induced
thymocyte apoptosis is associated with endogenous endonuclease
activation. Nature. 284:555–556. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bergsbaken T and Cookson BT: Macrophage
activation redirects Yersinia-infected host cell death from
apoptosis to caspase-1-dependent pyroptosis. PLoS Pathog.
3:e1612007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mizushima N and Komatsu M: Autophagy:
Renovation of cells and tissues. Cell. 147:728–741. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang D, Kang R, Berghe TV, Vandenabeele P
and Kroemer G: The molecular machinery of regulated cell death.
Cell Res. 29:347–364. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stockwell BR, Friedmann Angeli JP, Bayir
H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK,
Kagan VE, et al: Ferroptosis: A regulated cell death nexus linking
metabolism, redox biology, and disease. Cell. 171:273–285. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dixon SJ and Stockwell BR: The role of
iron and reactive oxygen species in cell death. Nat Chem Biol.
10:9–17. 2014. View Article : Google Scholar
|
|
27
|
Yang WS and Stockwell BR: Ferroptosis:
Death by lipid peroxidation. Trends Cell Biol. 26:165–176. 2016.
View Article : Google Scholar :
|
|
28
|
Liang D, Minikes AM and Jiang X:
Ferroptosis at the intersection of lipid metabolism and cellular
signaling. Mol Cell. 82:2215–2227. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen X, Kang R, Kroemer G and Tang D:
Broadening horizons: The role of ferroptosis in cancer. Nat Rev
Clin Oncol. 18:280–296. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gao GB, Chen L, Pan JF, Lei T, Cai X, Hao
Z, Wang Q, Shan G and Li J: LncRNA RGMB-AS1 inhibits HMOX1
ubiquitination and NAA10 activation to induce ferroptosis in
non-small cell lung cancer. Cancer Lett. 590:2168262024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R
and Tang D: Activation of the p62-Keap1-NRF2 pathway protects
against ferroptosis in hepatocellular carcinoma cells. Hepatology.
63:173–184. 2016. View Article : Google Scholar
|
|
32
|
Li J, Liu J, Zhou Z, Wu R, Chen X, Yu C,
Stockwell B, Kroemer G, Kang R and Tang D: Tumor-specific GPX4
degradation enhances ferroptosis-initiated antitumor immune
response in mouse models of pancreatic cancer. Sci Transl Med.
15:eadg30492023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ding Y, Chen X, Liu C, Ge W, Wang Q, Hao
X, Wang M, Chen Y and Zhang Q: Identification of a small molecule
as inducer of ferroptosis and apoptosis through ubiquitination of
GPX4 in triple negative breast cancer cells. J Hematol Oncol.
14:192021. View Article : Google Scholar
|
|
34
|
Zou Y, Palte MJ, Deik AA, Li H, Eaton JK,
Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dančík V, et al: A
GPX4-dependent cancer cell state underlies the clear-cell
morphology and confers sensitivity to ferroptosis. Nat Commun.
10:16172019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shen Z, Song J, Yung BC, Zhou Z, Wu A and
Chen X: Emerging strategies of cancer therapy based on ferroptosis.
Adv Mater. 30:e17040072018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Friedmann Angeli JP, Krysko DV and Conrad
M: Ferroptosis at the crossroads of cancer-acquired drug resistance
and immune evasion. Nat Rev Cancer. 19:405–414. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hassannia B, Vandenabeele P and Vanden
Berghe T: Targeting ferroptosis to iron out cancer. Cancer Cell.
35:830–849. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Angeli JPF, Shah R, Pratt DA and Conrad M:
Ferroptosis inhibition: Mechanisms and opportunities. Trends
Pharmacol Sci. 38:489–498. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mou Y, Wang J, Wu J, He D, Zhang C, Duan C
and Li B: Ferroptosis, a new form of cell death: Opportunities and
challenges in cancer. J Hematol Oncol. 12:342019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tang D, Chen X, Kang R and Kroemer G:
Ferroptosis: Molecular mechanisms and health implications. Cell
Res. 31:107–125. 2021. View Article : Google Scholar :
|
|
41
|
Chen X, Li J, Kang R, Klionsky DJ and Tang
D: Ferroptosis: Machinery and regulation. Autophagy. 17:2054–2081.
2021. View Article : Google Scholar :
|
|
42
|
Zeng F, Nijiati S, Tang L, Ye J, Zhou Z
and Chen X: Ferroptosis detection: From approaches to applications.
Angew Chem Int Ed Engl. 62:e2023003792023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Frey PA and Reed GH: The ubiquity of iron.
ACS Chem Biol. 7:1477–1481. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hentze MW, Muckenthaler MU and Andrews NC:
Balancing acts: Molecular control of mammalian iron metabolism.
Cell. 117:285–297. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gonciarz RL, Collisson EA and Renslo AR:
Ferrous Iron-dependent pharmacology. Trends Pharmacol Sci. 42:7–18.
2021. View Article : Google Scholar
|
|
46
|
Gao M, Monian P, Pan Q, Zhang W, Xiang J
and Jiang X: Ferroptosis is an autophagic cell death process. Cell
Res. 26:1021–1032. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Geng N, Shi BJ, Li SL, Zhong ZY, Li YC,
Xua WL, Zhou H and Cai JH: Knockdown of ferroportin accelerates
erastin-induced ferroptosis in neuroblastoma cells. Eur Rev Med
Pharmacol Sci. 22:3826–3836. 2018.PubMed/NCBI
|
|
48
|
Wang Y, Liu Y, Liu J, Kang R and Tang D:
NEDD4L-mediated LTF protein degradation limits ferroptosis. Biochem
Biophys Res Commun. 531:581–587. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Alvarez SW, Sviderskiy VO, Terzi EM,
Papagiannakopoulos T, Moreira AL, Adams S, Sabatini DM, Birsoy K
and Possemato R: NFS1 undergoes positive selection in lung tumours
and protects cells from ferroptosis. Nature. 551:639–643. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Du J, Wang T, Li Y, Zhou Y, Wang X, Yu X,
Ren X, An Y, Wu Y, Sun W, et al: DHA inhibits proliferation and
induces ferroptosis of leukemia cells through autophagy dependent
degradation of ferritin. Free Radic Biol Med. 131:356–369. 2019.
View Article : Google Scholar
|
|
51
|
Knutson MD: Non-transferrin-bound iron
transporters. Free Radic Biol Med. 133:101–111. 2019. View Article : Google Scholar
|
|
52
|
Song N, Zhang J, Zhai J, Hong J, Yuan C
and Liang M: Ferritin: A multifunctional nanoplatform for
biological detection, imaging diagnosis, and drug delivery. Acc
Chem Res. 54:3313–3325. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh
HJ III, Kang R and Tang D: Autophagy promotes ferroptosis by
degradation of ferritin. Autophagy. 12:1425–1428. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mancias JD, Wang X, Gygi SP, Harper JW and
Kimmelman AC: Quantitative proteomics identifies NCOA4 as the cargo
receptor mediating ferritinophagy. Nature. 509:105–109. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yang WS, Kim KJ, Gaschler MM, Patel M,
Shchepinov MS and Stockwell BR: Peroxidation of polyunsaturated
fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci
USA. 113:E4966–E4975. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yan B, Ai Y, Sun Q, Ma Y, Cao Y, Wang J,
Zhang Z and Wang X: Membrane Damage during ferroptosis is caused by
oxidation of phospholipids catalyzed by the oxidoreductases POR and
CYB5R1. Mol Cell. 81:355–369.e10. 2021. View Article : Google Scholar
|
|
57
|
Conrad M and Pratt DA: The chemical basis
of ferroptosis. Nat Chem Biol. 15:1137–1147. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kagan VE, Mao G, Qu F, Angeli JP, Doll S,
Croix CS, Dar HH, Liu B, Tyurin VA, Ritov VB, et al: Oxidized
arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem
Biol. 13:81–90. 2017. View Article : Google Scholar
|
|
59
|
Magtanong L, Ko PJ, To M, Cao JY, Forcina
GC, Tarangelo A, Ward CC, Cho K, Patti GJ, Nomura DK, et al:
Exogenous monounsaturated fatty acids promote a
Ferroptosis-resistant cell state. Cell Chem Biol. 26:420–432.e9.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tesfay L, Paul BT, Konstorum A, Deng Z,
Cox AO, Lee J, Furdui CM, Hegde P, Torti FM and Torti SV:
Stearoyl-CoA desaturase 1 protects ovarian cancer cells from
ferroptotic cell death. Cancer Res. 79:5355–5366. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chu B, Kon N, Chen D, Li T, Liu T, Jiang
L, Song S, Tavana O and Gu W: ALOX12 is required for p53-mediated
tumour suppression through a distinct ferroptosis pathway. Nat Cell
Biol. 21:579–591. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yang WS, SriRamaratnam R, Welsch ME,
Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji
AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by
GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ingold I, Berndt C, Schmitt S, Doll S,
Poschmann G, Buday K, Roveri A, Peng X, Porto Freitas F, Seibt T,
et al: Selenium utilization by GPX4 is required to prevent
hydroperoxide-induced ferroptosis. Cell. 172:409–422.e421. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ursini F and Maiorino M: Lipid
peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic
Biol Med. 152:175–185. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Dai C, Chen X, Li J, Comish P, Kang R and
Tang D: Transcription factors in ferroptotic cell death. Cancer
Gene Ther. 27:645–656. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Doll S, Freitas FP, Shah R, Aldrovandi M,
da Silva MC, Ingold I, Goya Grocin A, Xavier da Silva TN, Panzilius
E, Scheel CH, et al: FSP1 is a glutathione-independent ferroptosis
suppressor. Nature. 575:693–698. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Bersuker K, Hendricks JM, Li Z, Magtanong
L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, et al:
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit
ferroptosis. Nature. 575:688–692. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kraft VAN, Bezjian CT, Pfeiffer S,
Ringelstetter L, Müller C, Zandkarimi F, Merl-Pham J, Bao X,
Anastasov N, Kössl J, et al: GTP Cyclohydrolase
1/tetrahydrobiopterin counteract ferroptosis through lipid
remodeling. ACS Cent Sci. 6:41–53. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Soula M, Weber RA, Zilka O, Alwaseem H, La
K, Yen F, Molina H, Garcia-Bermudez J, Pratt DA, Birsoy K, et al:
Metabolic determinants of cancer cell sensitivity to canonical
ferroptosis inducers. Nat Chem Biol. 16:1351–1360. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee
H, Koppula P, Wu S, Zhuang L, Fang B, et al: DHODH-mediated
ferroptosis defence is a targetable vulnerability in cancer.
Nature. 593:586–590. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Liang D, Feng Y, Zandkarimi F, Wang H,
Zhang Z, Kim J, Cai Y, Gu W, Stockwell BR and Jiang X: Ferroptosis
surveillance independent of GPX4 and differentially regulated by
sex hormones. Cell. 186:2748–2764.e2722. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Lei G, Zhuang L and Gan B: The roles of
ferroptosis in cancer: Tumor suppression, tumor microenvironment,
and therapeutic interventions. Cancer Cell. 42:513–534. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
de Visser KE and Joyce JA: The evolving
tumor microenvironment: From cancer initiation to metastatic
outgrowth. Cancer Cell. 41:374–403. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Binnewies M, Roberts EW, Kersten K, Chan
V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI,
Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor
immune microenvironment (TIME) for effective therapy. Nat Med.
24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Elhanani O, Ben-Uri R and Keren L: Spatial
profiling technologies illuminate the tumor microenvironment.
Cancer Cell. 41:404–420. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Cui K, Wang K and Huang Z: Ferroptosis and
the tumor microenvironment. J Exp Clin Cancer Res. 43:3152024.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Bhowmick S, Banerjee S, Shridhar V and
Mondal S: Reprogrammed immuno-metabolic environment of cancer: The
driving force of ferroptosis resistance. Mol Cancer. 24:1612025.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kim R, Taylor D, Vonderheide RH and
Gabrilovich DI: Ferroptosis of immune cells in the tumor
microenvironment. Trends Pharmacol Sci. 44:542–552. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Zheng Y, Sun L, Guo J and Ma J: The
crosstalk between ferroptosis and anti-tumor immunity in the tumor
microenvironment: Molecular mechanisms and therapeutic controversy.
Cancer Commun (Lond). 43:1071–1096. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Demuynck R, Efimova I, Naessens F and
Krysko DV: Immunogenic ferroptosis and where to find it? J
Immunother Cancer. 9:e0034302021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Fucikova J, Kepp O, Kasikova L, Petroni G,
Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G and Galluzzi L:
Detection of immunogenic cell death and its relevance for cancer
therapy. Cell Death Dis. 11:10132020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Wen Q, Liu J, Kang R, Zhou B and Tang D:
The release and activity of HMGB1 in ferroptosis. Biochem Biophys
Res Commun. 510:278–283. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zhao YY, Lian JX, Lan Z, Zou KL, Wang WM
and Yu GT: Ferroptosis promotes anti-tumor immune response by
inducing immunogenic exposure in HNSCC. Oral Dis. 29:933–941. 2023.
View Article : Google Scholar
|
|
85
|
Han W, Duan X, Ni K, Li Y, Chan C and Lin
W: Co-delivery of dihydroartemisinin and pyropheophorbide-iron
elicits ferroptosis to potentiate cancer immunotherapy.
Biomaterials. 280:1213152022. View Article : Google Scholar :
|
|
86
|
Wan C, Sun Y, Tian Y, Lu L, Dai X, Meng J,
Huang J, He Q, Wu B, Zhang Z, et al: Irradiated tumor cell-derived
microparticles mediate tumor eradication via cell killing and
immune reprogramming. Sci Adv. 6:eaay97892020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Efimova I, Catanzaro E, Van der Meeren L,
Turubanova VD, Hammad H, Mishchenko TA, Vedunova MV, Fimognari C,
Bachert C, Coppieters F, et al: Vaccination with early ferroptotic
cancer cells induces efficient antitumor immunity. J Immunother
Cancer. 8:e0013692020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Liu J, Zhu S, Zeng L, Li J, Klionsky DJ,
Kroemer G, Jiang J, Tang D and Kang R: DCN released from
ferroptotic cells ignites AGER-dependent immune responses.
Autophagy. 18:2036–2049. 2022. View Article : Google Scholar :
|
|
89
|
Wiernicki B, Maschalidi S, Pinney J,
Adjemian S, Vanden Berghe T, Ravichandran KS and Vandenabeele P:
Cancer cells dying from ferroptosis impede dendritic Cell-mediated
Anti-tumor immunity. Nat Commun. 13:36762022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Han C, Ge M, Xing P, Xia T, Zhang C, Ma K,
Ma Y, Li S, Li W, Liu X, et al: Cystine deprivation triggers
CD36-mediated ferroptosis and dysfunction of tumor infiltrating
CD8+ T cells. Cell Death Dis. 15:1452024. View Article : Google Scholar :
|
|
91
|
Luo X, Gong HB, Gao HY, Wu YP, Sun WY, Li
ZQ, Wang G, Liu B, Liang L, Kurihara H, et al: Oxygenated
phosphatidylethanolamine navigates phagocytosis of ferroptotic
cells by interacting with TLR2. Cell Death Differ. 28:1971–1989.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Kim KS, Choi B, Choi H, Ko MJ and Kim DH
and Kim DH: Enhanced natural killer cell anti-tumor activity with
nanoparticles mediated ferroptosis and potential therapeutic
application in prostate cancer. J Nanobiotechnology. 20:4282022.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Drijvers JM, Gillis JE, Muijlwijk T,
Nguyen TH, Gaudiano EF, Harris IS, LaFleur MW, Ringel AE, Yao CH,
Kurmi K, et al: Pharmacologic screening identifies metabolic
vulnerabilities of CD8+ T cells. Cancer Immunol Res. 9:184–199.
2021. View Article : Google Scholar :
|
|
94
|
Arensman MD, Yang XS, Leahy DM,
Toral-Barza L, Mileski M, Rosfjord EC, Wang F, Deng S, Myers JS,
Abraham RT and Eng CH: Cystine-glutamate antiporter xCT deficiency
suppresses tumor growth while preserving antitumor immunity. Proc
Natl Acad Sci USA. 116:9533–9542. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Xu S, Chaudhary O, Rodríguez-Morales P,
Sun X, Chen D, Zappasodi R, Xu Z, Pinto AFM, Williams A, Schulze I,
et al: Uptake of oxidized lipids by the scavenger receptor CD36
promotes lipid peroxidation and dysfunction in CD8+ T cells in
tumors. Immunity. 54:1561–1577.e7. 2021. View Article : Google Scholar
|
|
96
|
Xu C, Sun S, Johnson T, Qi R, Zhang S,
Zhang J and Yang K: The glutathione peroxidase Gpx4 prevents lipid
peroxidation and ferroptosis to sustain Treg cell activation and
suppression of antitumor immunity. Cell Rep. 35:1092352021.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Sica A and Mantovani A: Macrophage
plasticity and polarization: In vivo veritas. J Clin Invest.
122:787–795. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Biswas SK and Mantovani A: Macrophage
plasticity and interaction with lymphocyte subsets: Cancer as a
paradigm. Nat Immunol. 11:889–896. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Kapralov AA, Yang Q, Dar HH, Tyurina YY,
Anthonymuthu TS, Kim R, St Croix CM, Mikulska-Ruminska K, Liu B,
Shrivastava IH, et al: Redox lipid reprogramming commands
susceptibility of macrophages and microglia to ferroptotic death.
Nat Chem Biol. 16:278–290. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Zhu H, Klement JD, Lu C, Redd PS, Yang D,
Smith AD, Poschel DB, Zou J, Liu D, Wang PG, et al: Asah2 represses
the p53-Hmox1 axis to protect Myeloid-derived suppressor cells from
ferroptosis. J Immunol. 206:1395–1404. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Ždralević M, Vučetić M, Daher B, Marchiq
I, Parks SK and Pouysségur J: Disrupting the 'Warburg effect'
re-routes cancer cells to OXPHOS offering a vulnerability point via
'ferroptosis'-induced cell death. Adv Biol Regul. 68:55–63. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Amos A, Amos A, Wu L and Xia H: The
Warburg effect modulates DHODH role in ferroptosis: A review. Cell
Commun Signal. 21:1002023. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Song X, Liu J, Kuang F, Chen X, Zeh HJ
III, Kang R, Kroemer G, Xie Y and Tang D: PDK4 dictates metabolic
resistance to ferroptosis by suppressing pyruvate oxidation and
fatty acid synthesis. Cell Rep. 34:1087672021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Dai Y, Cui C, Jiao D and Zhu X: JAK/STAT
signaling as a key regulator of ferroptosis: Mechanisms and
therapeutic potentials in cancer and diseases. Cancer Cell Int.
25:832025. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Yi J, Zhu J, Wu J, Thompson CB and Jiang
X: Oncogenic activation of PI3K-AKT-mTOR signaling suppresses
ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci USA.
117:31189–31197. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Garcia-Bermudez J, Baudrier L, Bayraktar
EC, Shen Y, La K, Guarecuco R, Yucel B, Fiore D, Tavora B,
Freinkman E, et al: Squalene accumulation in cholesterol
auxotrophic lymphomas prevents oxidative cell death. Nature.
567:118–122. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Warner GJ, Berry MJ, Moustafa ME, Carlson
BA, Hatfield DL and Faust JR: Inhibition of selenoprotein synthesis
by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine. J Biol
Chem. 275:28110–28119. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Qu L, He X, Tang Q, Fan X, Liu J and Lin
A: Iron metabolism, ferroptosis, and lncRNA in cancer: Knowns and
unknowns. J Zhejiang Univ Sci B. 23:844–862. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhang S, Xin W, Anderson GJ, Li R, Gao L,
Chen S, Zhao J and Liu S: Double-edge sword roles of iron in
driving energy production versus instigating ferroptosis. Cell
Death Dis. 13:402022. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
He Y, Ling Y, Zhang Z, Mertens RT, Cao Q,
Xu X, Guo K, Shi Q, Zhang X, Huo L, et al: Butyrate reverses
ferroptosis resistance in colorectal cancer by inducing
c-Fos-dependent xCT suppression. Redox Biol. 65:1028222023.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Cui W, Guo M, Liu D, Xiao P, Yang C, Huang
H, Liang C, Yang Y, Fu X, Zhang Y, et al: Gut microbial metabolite
facilitates colorectal cancer development via ferroptosis
inhibition. Nat Cell Biol. 26:124–137. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Cavalli G and Heard E: Advances in
epigenetics link genetics to the environment and disease. Nature.
571:489–499. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zhang X, Sui S, Wang L, Li H, Zhang L, Xu
S and Zheng X: Inhibition of tumor propellant glutathione
peroxidase 4 induces ferroptosis in cancer cells and enhances
anticancer effect of cisplatin. J Cell Physiol. 235:3425–3437.
2020. View Article : Google Scholar
|
|
115
|
Zhang X, Huang Z, Xie Z, Chen Y, Zheng Z,
Wei X, Huang B, Shan Z, Liu J, Fan S, et al: Homocysteine induces
oxidative stress and ferroptosis of nucleus pulposus via enhancing
methylation of GPX4. Free Radic Biol Med. 160:552–565. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Kim JW, Min DW, Kim D, Kim J, Kim MJ, Lim
H and Lee JY: GPX4 overexpressed non-small cell lung cancer cells
are sensitive to RSL3-induced ferroptosis. Sci Rep. 13:88722023.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Lee J, You JH, Kim MS and Roh JL:
Epigenetic reprogramming of epithelial-mesenchymal transition
promotes ferroptosis of head and neck cancer. Redox Biol.
37:1016972020. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Koppula P, Zhuang L and Gan B: Cystine
transporter SLC7A11/xCT in cancer: Ferroptosis, nutrient
dependency, and cancer therapy. Protein Cell. 12:599–620. 2021.
View Article : Google Scholar :
|
|
119
|
Liu J, Xia X and Huang P: xCT: A critical
molecule that links cancer metabolism to redox signaling. Mol Ther.
28:2358–2366. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Pontel LB, Bueno-Costa A, Morellato AE,
Carvalho Santos J, Roué G and Esteller M: Acute lymphoblastic
leukemia necessitates GSH-dependent ferroptosis defenses to
overcome FSP1-epigenetic silencing. Redox Biol. 55:1024082022.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Wang X, Kong X, Feng X and Jiang DS:
Effects of DNA, RNA, and protein methylation on the regulation of
ferroptosis. Int J Biol Sci. 19:3558–3575. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Lv D, Zhong C, Dixit D, Yang K, Wu Q,
Godugu B, Prager BC, Zhao G, Wang X, Xie Q, et al: EGFR promotes
ALKBH5 nuclear retention to attenuate N6-methyladenosine and
protect against ferroptosis in glioblastoma. Mol Cell.
83:4334–4351.e4337. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Wang J, Xiu M, Wang J, Gao Y and Li Y:
METTL16-SENP3-LTF axis confers ferroptosis resistance and
facilitates tumorigenesis in hepatocellular carcinoma. J Hematol
Oncol. 17:782024. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Wang Y, Hu J, Wu S, Fleishman JS, Li Y, Xu
Y, Zou W, Wang J, Feng Y, Chen J and Wang H: Targeting epigenetic
and posttranslational modifications regulating ferroptosis for the
treatment of diseases. Signal Transduct Target Ther. 8:4492023.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Wang Y, Yang L, Zhang X, Cui W, Liu Y, Sun
QR, He Q, Zhao S, Zhang GA, Wang Y and Chen S: Epigenetic
regulation of ferroptosis by H2B monoubiquitination and p53. EMBO
Rep. 20:e475632019. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Ma M, Kong P, Huang Y, Wang J, Liu X, Hu
Y, Chen X, Du C and Yang H: Activation of MAT2A-ACSL3 pathway
protects cells from ferroptosis in gastric cancer. Free Radic Biol
Med. 181:288–299. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Li H, Liu W, Zhang X, Wu F, Sun D and Wang
Z: Ketamine suppresses proliferation and induces ferroptosis and
apoptosis of breast cancer cells by targeting KAT5/GPX4 axis.
Biochem Biophys Res Commun. 585:111–116. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Zhang X, Du L, Qiao Y, Zhang X, Zheng W,
Wu Q, Chen Y, Zhu G, Liu Y, Bian Z, et al: Ferroptosis is governed
by differential regulation of transcription in liver cancer. Redox
Biol. 24:1012112019. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Zille M, Kumar A, Kundu N, Bourassa MW,
Wong VSC, Willis D, Karuppagounder SS and Ratan RR: Ferroptosis in
neurons and cancer cells is similar but differentially regulated by
histone deacetylase inhibitors. eNeuro. 6:ENEURO.0263-18.20192019.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Yadav P, Sharma P, Sundaram S, Venkatraman
G, Bera AK and Karunagaran D: SLC7A11/xCT is a target of miR-5096
and its restoration partially rescues miR-5096-mediated ferroptosis
and anti-tumor effects in human breast cancer cells. Cancer Lett.
522:211–224. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Deng SH, Wu DM, Li L, Liu T, Zhang T, Li
J, Yu Y, He M, Zhao YY, Han R and Xu Y: miR-324-3p reverses
cisplatin resistance by inducing GPX4-mediated ferroptosis in lung
adenocarcinoma cell line A549. Biochem Biophys Res Commun.
549:54–60. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Bao C, Zhang J, Xian SY and Chen F:
MicroRNA-670-3p suppresses ferroptosis of human glioblastoma cells
through targeting ACSL4. Free Radic Res. 55:853–864. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Ma LL, Liang L, Zhou D and Wang SW: Tumor
suppressor miR-424-5p abrogates ferroptosis in ovarian cancer
through targeting ACSL4. Neoplasma. 68:165–173. 2021. View Article : Google Scholar
|
|
134
|
Qi W, Li Z, Xia L, Dai J, Zhang Q, Wu C
and Xu S: LncRNA GABPB1-AS1 and GABPB1 regulate oxidative stress
during erastin-induced ferroptosis in HepG2 hepatocellular
carcinoma cells. Sci Rep. 9:161852019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Zhang Y, Guo S, Wang S, Li X, Hou D, Li H,
Wang L, Xu Y, Ma B, Wang H and Jiang X: LncRNA OIP5-AS1 inhibits
ferroptosis in prostate cancer with long-term cadmium exposure
through miR-128-3p/SLC7A11 signaling. Ecotoxicol Environ Saf.
220:1123762021. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Huang B, Wang H, Liu S, Hao M, Luo D, Zhou
Y, Huang Y, Nian Y, Zhang L, Chu B and Yin C:
Palmitoylation-dependent regulation of GPX4 suppresses ferroptosis.
Nat Commun. 16:8672025. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Gong R, Wan X, Jiang S, Guan Y, Li Y,
Jiang T, Chen Z, Zhong C, He L, Xiang Z, et al: GPX4-AUTAC induces
ferroptosis in breast cancer by promoting the selective autophagic
degradation of GPX4 mediated by TRAF6-p62. Cell Death Differ. May
20–2025. View Article : Google Scholar : Epub ahead of
print.
|
|
138
|
Yao L, Yang N, Zhou W, Akhtar MH, Zhou W,
Liu C, Song S, Li Y, Han W and Yu C: Exploiting cancer
vulnerabilities by blocking of the DHODH and GPX4 pathways: A
multifunctional Bodipy/PROTAC nanoplatform for the efficient
synergistic ferroptosis therapy. Adv Healthc Mater.
12:e23008712023. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Dong J, Ma F, Cai M, Cao F, Li H, Liang H,
Li Y, Ding G, Li J, Cheng X and Qin JJ: Heat shock protein 90
interactome-mediated proteolysis targeting chimera (HIM-PROTAC)
degrading glutathione peroxidase 4 to trigger ferroptosis. J Med
Chem. 67:16712–16736. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Wang S, Zhu L, Li T, Lin X, Zheng Y, Xu D,
Guo Y, Zhang Z, Fu Y, Wang H, et al: Disruption of MerTK increases
the efficacy of checkpoint inhibitor by enhancing ferroptosis and
immune response in hepatocellular carcinoma. Cell Rep Med.
5:1014152024. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Lamperis SM, McMahon KM, Calvert AE, Rink
JS, Vasan K, Pandkar MR, Crentsil EU, Chalmers ZR, McDonald NR,
Kosmala CJ, et al: CRISPR screen reveals a simultaneous targeted
mechanism to reduce cancer cell selenium and increase lipid
oxidation to induce ferroptosis. Proc Natl Acad Sci USA.
122:e25028761222025. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Gao J, Ye T, Miao H, Liu M, Wen L, Tian Y,
Fu Z, Sun L, Wang L and Wang Y: Antibody-functionalized iron-based
nanoplatform for ferroptosis-augmented targeted therapy of
HER2-positive breast cancer. Bioact Mater. 52:702–718.
2025.PubMed/NCBI
|
|
143
|
Burris HA III, Okusaka T, Vogel A, Lee MA,
Takahashi H, Breder V, Blanc JF, Li J, Bachini M, Żotkiewicz M, et
al: Durvalumab plus gemcitabine and cisplatin in advanced biliary
tract cancer (TOPAZ-1): Patient-reported outcomes from a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol. 25:626–635. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse
J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, et al: Pembrolizumab
in combination with gemcitabine and cisplatin compared with
gemcitabine and cisplatin alone for patients with advanced biliary
tract cancer (KEYNOTE-966): A randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet. 401:1853–1865. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Zhang C, Liu X, Jin S, Chen Y and Guo R:
Ferroptosis in cancer therapy: A novel approach to reversing drug
resistance. Mol Cancer. 21:472022. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Cheok CF, Verma CS, Baselga J and Lane DP:
Translating p53 into the clinic. Nat Rev Clin Oncol. 8:25–37. 2011.
View Article : Google Scholar
|
|
147
|
Bykov VJN, Eriksson SE, Bianchi J and
Wiman KG: Targeting mutant p53 for efficient cancer therapy. Nat
Rev Cancer. 18:89–102. 2018. View Article : Google Scholar
|
|
148
|
Jiang L, Kon N, Li T, Wang SJ, Su T,
Hibshoosh H, Baer R and Gu W: Ferroptosis as a p53-mediated
activity during tumour suppression. Nature. 520:57–62. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Zeng C, Lin J, Zhang K, Ou H, Shen K, Liu
Q, Wei Z, Dong X, Zeng X, Zeng L, et al: SHARPIN promotes cell
proliferation of cholangiocarcinoma and inhibits ferroptosis via
p53/SLC7A11/GPX4 signaling. Cancer Sci. 113:3766–3775. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Ma S, Ma Y, Qi F, Lei J, Chen F, Sun W,
Wang D, Zhou S, Liu Z, Lu Z, et al: HSDL2 knockdown promotes the
progression of cholangiocarcinoma by inhibiting ferroptosis through
the P53/SLC7A11 axis. World J Surg Oncol. 21:2932023. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Cai C, Zhu Y, Mu J, Liu S, Yang Z, Wu Z,
Zhao C, Song X, Ye Y, Gu J, et al: DNA methylation of RUNX3
promotes the progression of gallbladder cancer through repressing
SLC7A11-mediated ferroptosis. Cell Signal. 108:1107102023.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Yin Z, Liu Q, Gao Y, Wang R, Qi Y, Wang D,
Chen L, Yin X, He M and Li W: GOLPH3 promotes tumor malignancy via
inhibition of ferroptosis by upregulating SLC7A11 in
cholangiocarcinoma. Mol Carcinog. 63:912–925. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Toshida K, Itoh S, Iseda N, Izumi T,
Yoshiya S, Toshima T, Ninomiya M, Iwasaki T, Oda Y and Yoshizumi T:
Impact of TP53-induced glycolysis and apoptosis regulator on
malignant activity and resistance to ferroptosis in intrahepatic
cholangiocarcinoma. Cancer science. 115:170–183. 2024. View Article : Google Scholar
|
|
154
|
Dodson M, Castro-Portuguez R and Zhang DD:
NRF2 plays a critical role in mitigating lipid peroxidation and
ferroptosis. Redox Biol. 23:1011072019. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Kerins MJ and Ooi A: The roles of NRF2 in
modulating cellular iron homeostasis. Antioxid Redox Signal.
29:1756–1773. 2018. View Article : Google Scholar :
|
|
156
|
Huang HX, Yang G, Yang Y, Yan J, Tang XY
and Pan Q: TFAP2A is a novel regulator that modulates ferroptosis
in gallbladder carcinoma cells via the Nrf2 signalling axis. Eur
Rev Med Pharmacol Sci. 24:4745–4755. 2020.PubMed/NCBI
|
|
157
|
Zheng X, Li H, Lin J, Li P, Yang X, Luo Z
and Jin L: METTL3-mediated m6A modification promotes
chemoresistance of intrahepatic cholangiocarcinoma by up-regulating
NRF2 to inhibit ferroptosis in cisplatin-resistant cells. J
Chemother. 37:596–606. 2025. View Article : Google Scholar
|
|
158
|
Zhao S, Cao J, Liang R, Peng T, Wu S, Liu
Z, Wu Y, Song L, Sun C, Liu Y, et al: METTL16 suppresses
ferroptosis in cholangiocarcinoma by promoting ATF4 via
m6A modification. Int J Biol Sci. 21:189–203. 2025.
View Article : Google Scholar :
|
|
159
|
Ursini F, Maiorino M, Valente M, Ferri L
and Gregolin C: Purification from pig liver of a protein which
protects liposomes and biomembranes from peroxidative degradation
and exhibits glutathione peroxidase activity on phosphatidylcholine
hydroperoxides. Biochim Biophys Acta. 710:197–211. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Yant LJ, Ran Q, Rao L, Van Remmen H,
Shibatani T, Belter JG, Motta L, Richardson A and Prolla TA: The
selenoprotein GPX4 is essential for mouse development and protects
from radiation and oxidative damage insults. Free Radic Biol Med.
34:496–502. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Shah R, Shchepinov MS and Pratt DA:
Resolving the role of lipoxygenases in the initiation and execution
of ferroptosis. ACS Cent Sci. 4:387–396. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Hori Y, Yoh T, Nishino H, Okura K,
Kurimoto M, Takamatsu Y, Satoh M, Nishio T, Koyama Y, Ishii T, et
al: Ferroptosis-related gene glutathione peroxidase 4 promotes
reprogramming of glucose metabolism via Akt-mTOR axis in
intrahepatic cholangiocarcinoma. Carcinogenesis. 45:119–130. 2024.
View Article : Google Scholar
|
|
163
|
Lei S, Cao W, Zeng Z, Zhang Z, Jin B, Tian
Q, Wu Y, Zhang T, Li D, Hu C, et al: JUND/linc00976 promotes
cholangiocarcinoma progression and metastasis, inhibits ferroptosis
by regulating the miR-3202/GPX4 axis. Cell Death Dis. 13:9672022.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Zhu Z, Zheng Y, He H, Yang L, Yang J, Li
M, Dai W and Huang H: FBXO31 sensitizes cancer stem cells-like
cells to cisplatin by promoting ferroptosis and facilitating
proteasomal degradation of GPX4 in cholangiocarcinoma. Liver Int.
42:2871–2888. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Chen ZW, Shan JJ, Chen M, Wu Z, Zhao YM,
Zhu HX, Jin X, Wang YX, Wu YB, Xiang Z, et al: Targeting GPX4 to
induce ferroptosis overcomes chemoresistance mediated by the
PAX8-AS1/GPX4 axis in intrahepatic cholangiocarcinoma. Adv Sci
(Weinh). 12:e010422025. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Doll S, Proneth B, Tyurina YY, Panzilius
E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A,
et al: ACSL4 dictates ferroptosis sensitivity by shaping cellular
lipid composition. Nat Chem Biol. 13:91–98. 2017. View Article : Google Scholar :
|
|
167
|
Gan B: ACSL4, PUFA, and ferroptosis: New
arsenal in anti-tumor immunity. Signal Transduct Target Ther.
7:1282022. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Liu S, Fan S, Wang Y, Chen R, Wang Z,
Zhang Y, Jiang W, Chen Y, Xu X, Yu Y, et al: ACSL4 serves as a
novel prognostic biomarker correlated with immune infiltration in
Cholangiocarcinoma. BMC Cancer. 23:4442023. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Liao P, Wang W, Wang W, Kryczek I, Li X,
Bian Y, Sell A, Wei S, Grove S, Johnson JK, et al: CD8+ T cells and
fatty acids orchestrate tumor ferroptosis and immunity via ACSL4.
Cancer Cell. 40:365–378.e6. 2022. View Article : Google Scholar :
|
|
170
|
Wang Y, Hu M, Cao J, Wang F, Han JR, Wu
TW, Li L, Yu J, Fan Y, Xie G, et al: ACSL4 and polyunsaturated
lipids support metastatic extravasation and colonization. Cell.
188:412–429.e27. 2025. View Article : Google Scholar
|
|
171
|
Huang Q, Ru Y, Luo Y, Luo X, Liu D, Ma Y,
Zhou X, Linghu M, Xu W, Gao F and Huang Y: Identification of a
targeted ACSL4 inhibitor to treat ferroptosis-related diseases. Sci
Adv. 10:eadk12002024. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Liu L, Li Y, Cao D, Qiu S, Li Y, Jiang C,
Bian R, Yang Y, Li L, Li X, et al: SIRT3 inhibits gallbladder
cancer by induction of AKT-dependent ferroptosis and blockade of
epithelial-mesenchymal transition. Cancer Lett. 510:93–104. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Sae-Fung A, Vinayavekhin N, Fadeel B and
Jitkaew S: ACSL3 is an unfavorable prognostic marker in
cholangiocarcinoma patients and confers ferroptosis resistance in
cholangiocarcinoma cells. NPJ Precis Oncol. 8:2842024. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Wang P, Hu Z, Yu S, Su S, Wu R, Chen C, Ye
Y, Wang H, Ye X, Zhou Z, et al: A novel protein encoded by
circFOXP1 enhances ferroptosis and inhibits tumor recurrence in
intrahepatic cholangiocarcinoma. Cancer Lett. 598:2170922024.
View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Shi X, Yang J, Wang M, Xia L, Zhang L and
Qiao S: Hsa_circ_0050900 affects ferroptosis in intrahepatic
cholangiocarcinoma cells by targeting hsa-miR-605-3p to regulate
SLC3A2. Oncol Lett. 27:22024. View Article : Google Scholar
|
|
176
|
Toshida K, Itoh S, Iseda N, Izumi T, Bekki
Y, Yoshiya S, Toshima T, Iwasaki T, Oda Y and Yoshizumi T: The
association of transferrin receptor with prognosis and biologic
role in intrahepatic cholangiocarcinoma. Ann Surg Oncol.
31:8627–8637. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Wang X, Duan W, Ma Z, Wen H, Mao X and Liu
C: ETV4/ALYREF-mediated glycolytic metabolism through PKM2 enhances
resistance to ferroptosis and promotes the development of
intrahepatic cholangiocarcinoma. Cancer Metab. 13:192025.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Liu C, Zhang C, Wu H, Zhao Z, Wang Z,
Zhang X, Yang J, Yu W, Lian Z, Gao M and Zhou L: The
AKR1C1-CYP1B1-cAMP signaling axis controls tumorigenicity and
ferroptosis susceptibility of extrahepatic cholangiocarcinoma. Cell
Death Differ. 32:506–520. 2025. View Article : Google Scholar
|
|
179
|
Zhang Q, Zhou J, Zhai D, Jiang Q, Yang M
and Zhou M: Gut microbiota regulates the ALK5/NOX1 axis by altering
glutamine metabolism to inhibit ferroptosis of intrahepatic
cholangiocarcinoma cells. Biochim Biophys Acta Mol Basis Dis.
1870:1671522024. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Amontailak S, Titapun A, Jusakul A, Thanan
R, Kimawaha P, Jamnongkan W, Thanee M, Sirithawat P and Techasen A:
Prognostic values of Ferroptosis-related proteins ACSL4, SLC7A11,
and CHAC1 in cholangiocarcinoma. Biomedicines. 12:20912024.
View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Saisomboon S, Kariya R, Boonnate P,
Sawanyawisuth K, Cha'on U, Luvira V, Chamgramol Y, Pairojkul C,
Seubwai W, Silsirivanit A, et al: Diminishing acetyl-CoA
carboxylase 1 attenuates CCA migration via AMPK-NF-κB-snail axis.
Biochim Biophys Acta Mol Basis Dis. 1869:1666942023. View Article : Google Scholar
|
|
182
|
Wang J, Zhang M, Zhang L, Cai H, Zhou S,
Zhang J and Wang Y: Correlation of Nrf2, HO-1, and MRP3 in
gallbladder cancer and their relationships to clinicopathologic
features and survival. J Surg Res. 164:e99–e105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Sarcognato S, Sacchi D, Fabris L, Zanus G,
Gringeri E, Niero M, Gallina G and Guido M: Ferroptosis in
intrahepatic cholangiocarcinoma: IDH1(105GGT) single nucleotide
polymorphism is associated with its activation and better
prognosis. Front Med (Lausanne). 9:8862292022. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Rizzato M, Brignola S, Munari G, Gatti M,
Dadduzio V, Borga C, Bergamo F, Pellino A, Angerilli V, Mescoli C,
et al: Prognostic impact of FGFR2/3 alterations in patients with
biliary tract cancers receiving systemic chemotherapy: The BITCOIN
study. Eur J Cancer. 166:165–175. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Qian Y, Liang X, Kong P, Cheng Y, Cui H,
Yan T, Wang J, Zhang L, Liu Y, Guo S, et al: Elevated DHODH
expression promotes cell proliferation via stabilizing β-catenin in
esophageal squamous cell carcinoma. Cell Death Dise. 11:8622020.
View Article : Google Scholar
|
|
186
|
Hu J, Jiang Q, Mao W, Zhong S, Sun H and
Mao K: STARD7 could be an immunological and prognostic biomarker:
From pan-cancer analysis to hepatocellular carcinoma validation.
Discov Oncol. 15:5432024. View Article : Google Scholar
|
|
187
|
Sun J, Zhou C, Ma Q, Chen W, Atyah M, Yin
Y, Fu P, Liu S, Hu B, Ren N and Zhou H: High GCLC level in tumor
tissues is associated with poor prognosis of hepatocellular
carcinoma after curative resection. J Cancer. 10:3333–3343. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Wang M, Lu Y, Wang H, Wu Y, Xu X and Li Y:
High ATF4 expression is associated with poor prognosis, amino acid
metabolism, and autophagy in gastric cancer. Front Oncol.
11:7401202021. View Article : Google Scholar
|
|
189
|
Luis G, Godfroid A, Nishiumi S, Cimino J,
Blacher S, Maquoi E, Wery C, Collignon A, Longuespée R,
Montero-Ruiz L, et al: Tumor resistance to ferroptosis driven by
Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid
Biding Protein-4 (FABP4) in tumor microenvironment promote tumor
recurrence. Redox Biol. 43:1020062021. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Wei JL, Wu SY, Yang YS, Xiao Y, Jin X, Xu
XE, Hu X, Li DQ, Jiang YZ and Shao ZM: GCH1 induces
immunosuppression through metabolic reprogramming and IDO1
upregulation in triple-negative breast cancer. J Immunother Cancer.
9:e0023832021. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Wen F, Ling H, Ran R, Li X, Wang H, Liu Q,
Li M and Yu T: LPCAT3 regulates the proliferation and metastasis of
serous ovarian cancer by modulating arachidonic acid. Transl Oncol.
52:1022562025. View Article : Google Scholar :
|
|
192
|
Takahara H, Kanazawa T, Oshita H, Tomita
Y, Hananoi Y, Ishibashi S, Ikeda M, Furukawa A, Kinoshita M,
Yamamoto K, et al: GPX4 and FSP1 expression in lung adenocarcinoma:
Prognostic implications and Ferroptosis-based therapeutic
strategies. Cancers (Basel). 16:38882024. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Su L, Huang Y, Zheng L, Zhu Z, Wu Y and Li
P: Isocitrate dehydrogenase 1 mutation in cholangiocarcinoma
impairs tumor progression by sensitizing cells to ferroptosis. Open
Med (Wars). 17:863–870. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Abou-Alfa GK, Macarulla T, Javle MM,
Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ,
Bridgewater J, et al: Ivosidenib in IDH1-mutant,
chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A
multicentre, randomised, double-blind, placebo-controlled, phase 3
study. Lancet Oncol. 21:796–807. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Dong S, An S, Liu Q, Wang X, Hu Y and
Jiang A: Study on the synergistic mechanism of photodynamic therapy
combined with ferroptosis inducer to induce ferroptosis in
cholangiocarcinoma. Lancet Oncol. 56:845–853. 2024.
|
|
196
|
Li S, Chen X, Shi H, Yi M, Xiong B and Li
T: Tailoring traditional Chinese medicine in cancer therapy. Mol
Cancer. 24:272025. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Xi Z, Dai R, Ze Y, Jiang X, Liu M and Xu
H: Traditional Chinese medicine in lung cancer treatment. Mol
Cancer. 24:572025. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Wu J, Tang G, Cheng CS, Yeerken R, Chan
YT, Fu Z, Zheng YC, Feng Y and Wang N: Traditional Chinese medicine
for the treatment of cancers of hepatobiliary system: From clinical
evidence to drug discovery. Mol Cancer. 23:2182024. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Kim HI, Lee SJ, Choi YJ, Kim MJ, Kim TY
and Ko SG: Quercetin induces apoptosis in glioblastoma cells by
suppressing Axl/IL-6/STAT3 signaling pathway. Am J Chin Med.
49:767–784. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Mohammed HA, Sulaiman GM, Anwar SS,
Tawfeeq AT, Khan RA, Mohammed SAA, Al-Omar MS, Alsharidah M, Rugaie
OA and Al-Amiery AA: Quercetin against MCF7 and CAL51 breast cancer
cell lines: Apoptosis, gene expression and cytotoxicity of
nano-quercetin. Nanomedicine (Lond). 16:1937–1961. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Song Y, Zhang Z, Chai Q, Zheng H, Qi Y,
Xia G, Yu Z, Yang R, Huang J, Li Y, et al: Quercetin inhibits
intrahepatic cholangiocarcinoma by inducing ferroptosis and
inhibiting invasion via the NF-[Formula: See text]B pathway. Am J
Chin Med. 51:701–721. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Song Y, Zhang Z, Chai Q, Zheng H, Qi Y,
Xia G, Yu Z, Yang R, Huang J, Li Y, et al: ERRATUM: Quercetin
inhibits intrahepatic cholangiocarcinoma by inducing ferroptosis
and inhibiting invasion via the NF-[Formula: See text]B pathway. Am
J Chin Med. 51:1613–1614. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Chen C, Shenoy AK, Padia R, Fang D, Jing
Q, Yang P, Su SB and Huang S: Suppression of lung cancer
progression by isoliquiritigenin through its metabolite 2, 4, 2',
4'-Tetrahydroxychalcone. J Exp Clin Cancer Res. 37:2432018.
View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Chen C, Huang S, Chen CL, Su SB and Fang
DD: Isoliquiritigenin inhibits ovarian cancer metastasis by
reversing Epithelial-to-mesenchymal transition. Molecules.
24:37252019. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Wang Z, Li W, Wang X, Zhu Q, Liu L, Qiu S,
Zou L, Liu K, Li G, Miao H, et al: Isoliquiritigenin induces HMOX1
and GPX4-mediated ferroptosis in gallbladder cancer cells. Chin Med
J (Engl). 136:2210–2220. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Wang Z, Zhang Y, Shen Y, Zhu C, Qin X and
Gao Y: Liquidambaric acid inhibits cholangiocarcinoma progression
by disrupting the STAMBPL1/NRF2 positive feedback loop.
Phytomedicine. 136:1563032025. View Article : Google Scholar
|
|
207
|
Zhao J, Shi L, Yang Y, Zhu J, Zhou Z, Dong
P, Liu S, Yang Z and Gong W: Wu-Mei-Wan promotes ferroptosis in
gallbladder cancer through STAT3 negative regulation: An integrated
HPLC, proteomics, network pharmacology, and experimental validation
study. J Ethnopharmacol. 347:1196712025. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Zhu J, Xiong Y, Zhang Y, Liang H, Cheng K,
Lu Y, Cai G, Wu Y, Fan Y, Chen X, et al: Simvastatin overcomes the
pPCK1-pLDHA-SPRINGlac axis-mediated ferroptosis and
chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic
cholangiocarcinoma. Cancer Commun (Lond). 45:1038–1071. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Li W, Wang Z, Lin R, Huang S, Miao H, Zou
L, Liu K, Cui X, Wang Z, Zhang Y, et al: Lithocholic acid inhibits
gallbladder cancer proliferation through interfering
glutaminase-mediated glutamine metabolism. Biochem Pharmacol.
205:1152532022. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Pham TC, Nguyen VN, Choi Y, Lee S and Yoon
J: Recent strategies to develop innovative photosensitizers for
enhanced photodynamic therapy. Chem Rev. 121:13454–13619. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Brown SB, Brown EA and Walker I: The
present and future role of photodynamic therapy in cancer
treatment. Lancet Oncol. 5:497–508. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Alzeibak R, Mishchenko TA, Shilyagina NY,
Balalaeva IV, Vedunova MV and Krysko DV: Targeting immunogenic
cancer cell death by photodynamic therapy: Past, present and
future. J Immunother Cancer. 9:e0019262021. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Yan X, Li Z, Chen H, Yang F, Tian Q and
Zhang Y: Photodynamic therapy inhibits cancer progression and
induces ferroptosis and apoptosis by targeting P53/GPX4/SLC7A11
signaling pathways in cholangiocarcinoma. Photodiagnosis Photodyn
Ther. 47:1041042024. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
An W, Zhang K, Li G, Zheng S, Cao Y and
Liu J: Hypericin mediated photodynamic therapy induces ferroptosis
via inhibiting the AKT/mTORC1/GPX4 axis in cholangiocarcinoma.
Transl Oncol. 52:1022342025. View Article : Google Scholar :
|
|
215
|
Huang YP, Wang YX, Zhou H, Liu ZT, Zhang
ZJ, Xiong L, Zou H and Wen Y: Surufatinib combined with
photodynamic therapy induces ferroptosis to inhibit
cholangiocarcinoma in vitro and in tumor models. Front Pharmacol.
15:12882552024. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Wang W, Gao Y, Xu J, Zou T, Yang B, Hu S,
Cheng X, Xia Y and Zheng Q: A NRF2 regulated and the
immunosuppressive microenvironment reversed nanoplatform for
cholangiocarcinoma Photodynamic-Gas therapy. Adv Sci (Weinh).
11:e23071432024. View Article : Google Scholar : PubMed/NCBI
|
